These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 29500555)

  • 21. Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
    Gasteiger C; Lobo M; Dalbeth N; Petrie KJ
    Rheumatol Int; 2021 Jan; 41(1):163-171. PubMed ID: 32300866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.
    Moots R; Azevedo V; Coindreau JL; Dörner T; Mahgoub E; Mysler E; Scheinberg M; Marshall L
    Curr Rheumatol Rep; 2017 Jun; 19(6):37. PubMed ID: 28623625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.
    Liu Y; Yang M; Garg V; Wu EQ; Wang J; Skup M
    Adv Ther; 2019 Aug; 36(8):1851-1877. PubMed ID: 31168766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.
    Yin Y; McDermott C; Lockhart C
    J Manag Care Spec Pharm; 2023 Sep; 29(9):985-998. PubMed ID: 37610110
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis.
    Renton WD; Leveret H; Guly C; Smee H; Leveret J; Ramanan AV
    Pediatr Rheumatol Online J; 2019 Oct; 17(1):67. PubMed ID: 31585539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
    Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
    Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.
    Bloomfield D; D'Andrea E; Nagar S; Kesselheim A
    JAMA Oncol; 2022 Apr; 8(4):537-545. PubMed ID: 35113135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacists' Perspectives of Biosimilars: A Systematic Review.
    Mohd Sani N; Aziz Z; Panickar R; Kamarulzaman A
    BioDrugs; 2022 Jul; 36(4):489-508. PubMed ID: 35776294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The design of clinical trials to support the switching and alternation of biosimilars.
    Faccin F; Tebbey P; Alexander E; Wang X; Cui L; Albuquerque T
    Expert Opin Biol Ther; 2016 Dec; 16(12):1445-1453. PubMed ID: 27666115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars in supportive care.
    Foreman E
    Curr Opin Oncol; 2020 Jul; 32(4):282-288. PubMed ID: 32541314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.